Bortezomib Injection IP 2 mg

Bortezomib injection IP 2 mg is an Indian presentation of a proteasome inhibitor that most of the world buys in 3.5 mg vials. Indian manufacturers build the 2 mg vial to Indian Pharmacopoeia standards, and brands including Bortezom, Bortesam, and Bortemib all sell at this strength. Inside is a sterile lyophilized cake of bortezomib held as the mannitol boronic ester, with mannitol and nitrogen the only other contents. Torso supplies it as part of an oncology portfolio built for hospital and distributor demand.

The product is not ready to use. It arrives as a dry cake that the hospital pharmacy reconstitutes with 0.9 percent sodium chloride shortly before administration, and the mannitol boronic ester form is what holds bortezomib stable in that dry state. The prepared solution carries no preservative and has to be given within eight hours of mixing, so vials are opened against the day list rather than in advance.

For a distributor, the handling profile is what separates this product from much of the oncology shelf. Bortezomib holds at controlled room temperature, so it moves from plant to hospital with no cold chain to fund or monitor. Light is what the carton guards against. The molecule has been on the WHO Model List of Essential Medicines since 2019 for plasma cell myeloma, listed there at 3.5 mg, which is one more place the international strength and the Indian vial part company.

Bortezomib Injection IP 2 mg Uses

Approved labeling covers two malignancies and nothing beyond them:

• Multiple myeloma in patients who have had no prior treatment.
• Multiple myeloma where the disease has progressed after at least one earlier therapy.
• Mantle cell lymphoma in previously untreated patients.
• Mantle cell lymphoma that is relapsed or refractory.

Nothing outside those four situations is approved. This page records them for trade buyers rather than recommending treatment.

Route is where this product differs from most cytotoxic vials, because it has two and they are not interchangeable in effect. The vial reconstitutes with 0.9 percent sodium chloride only, to a different concentration for each.

The neuropathy column is the reason the choice matters, and those figures come from the randomized comparison in relapsed myeloma. Dosing itself is calculated against body surface area and stays with the treating oncologist. Handling at the pharmacy bench follows hazardous drug procedure, gloves and protective clothing included, the same as a docetaxel vial.

Bortezomib Injection IP 2 mg Side Effects

Peripheral neuropathy is the reaction that defines this molecule. It is dose-limiting; it is often what forces a schedule change, and the subcutaneous route roughly halves it. Grade 3 or worse neuropathy occurred at 6 percent subcutaneously against 16 percent intravenously in the same trial.

Beyond that, the common reactions recorded on the label group as follows:

• Nervous system: peripheral neuropathy and paresthesia.
• Blood counts: thrombocytopenia, anemia and neutropenia, with platelets following a cyclical pattern across each treatment cycle.
• Gastrointestinal: nausea, diarrhea, constipation, vomiting and reduced appetite.
• General: fatigue, pyrexia, headache and myalgia.
• Other: breathlessness, rash and herpes zoster.

Two items sit above that list and rarely appear on retail listings:

• Bortezomib is fatal if given by the intrathecal route. It is contraindicated that way, and the warning exists because the error has killed patients.
• At least 72 hours must pass between two consecutive doses. The interval is part of the approved schedule, not a precaution.

Bortezomib Injection IP 2 mg Manufacturer

Torso Healthcare operates as a WHO GMP-certified third-party and PCD manufacturer, and a lyophilized cytotoxic product of this kind runs on a sterile injectable line with containment, dedicated areas, and operator protection applied from dispensing through to packing. The freeze-drying cycle and the release testing carry most of the production cost on a product where the active content per vial is only 2 mg.

Buyers approach a bortezomib injection IP 2 mg supplier for one of two reasons. Either an oncology range needs a proteasome inhibitor it does not yet carry, or a brand owner wants the vial under a label of their own without building a cytotoxic facility. Both run the same way here, and the questions any serious buyer among oncology drug makers asks come down to containment and documentation. To open a file, send your vial count with the destination market and the artwork you intend to use.

Bortezomib Injection IP 2 mg Price in India

The bortezomib injection IP 2 mg price in India is MRP 2,180 INR per vial for TOSOVEL-2MG Injection. Presentation sets the floor, because a lyophilized cytotoxic is expensive to make regardless of how little drug the vial holds. Containment, the freeze-drying cycle, and sterility release all land on a single 2 mg unit.

Vial count then moves the figure. Batch pricing falls as the number of vials in the order rises, and a carton quantity priced for a hospital tender does not read the same as a trial quantity. Send your monthly requirement with the destination market and the team will come back with current rates.

Frequently Asked Questions

Why is the Indian vial 2 mg when international labeling is 3.5 mg?

The 3.5 mg vial is the originator presentation, and the one most reference labeling describes. Indian manufacturers produce a 2 mg vial to Indian Pharmacopoeia standards, which is why the strength appears across Indian brands and not on imported packs. The molecule and the handling are identical. Only the fill differs.

Can the same vial be given subcutaneously and intravenously?

Yes, but it is reconstituted differently for each. A 2 mg vial takes 2 mL of 0.9 percent sodium chloride for intravenous use, giving 1 mg per mL delivered as a three- to five-second bolus, or 0.8 mL for subcutaneous use, giving 2.5 mg per mL. Using the wrong volume for the route gives the wrong concentration.

How long does the reconstituted solution hold?

Eight hours, and that is a total figure rather than a storage figure. The reconstituted product carries no preservative, may be held at 20 to 25°C, and the eight hours covers time in the vial, time in the syringe, and exposure to normal indoor lighting combined. Unopened vials stay in the carton at 25°C and carry a 24-month shelf life from manufacture.

Can we order the 3.5 mg vial instead of the 2 mg?

Say so when you send volumes, because the fill, the carton, and the quote all change with the strength. This page covers the 2 mg vial, the Indian Pharmacopoeia presentation that Indian brands sell. The 3.5 mg vial is the international standard, so export buyers often want that one. Route options, handling, and PCD oncology supply terms stay the same either way.

Do you supply this under our own bortezomib injection IP 2 mg brand name?

Yes. The vial ships as TOSOVEL-2MG Injection, or under a brand you own, with your artwork on the mono carton, through either third-party manufacturing or a PCD arrangement. The product, the line, and the quality release do not change. Only the name on the carton does.

Sources: Composition, reconstitution volumes and concentrations, storage, in-use stability, and hazardous handling from the approved bortezomib prescribing information (VELCADE label, section 16). Indications, the intrathecal contraindication, the 72-hour dosing interval, and the subcutaneous versus intravenous peripheral neuropathy rates from the Health Canada product monograph. Essential Medicines listing from the WHO Model List entry for bortezomib. Indian 2 mg brand presentations confirmed against current Indian pharmacy and trade listings, November 2026. Brand, price, and shelf life confirmed against the Torso product record.

Disclaimer: This page is written for pharmaceutical companies, distributors, PCD franchise partners and healthcare professionals. Bortezomib is a prescription-only cytotoxic product for administration by trained oncology staff. The information here supports trade and supply decisions, makes no claim of cure or outcome, and does not replace advice from a qualified doctor.